Abstract: The present invention relates to intercellular adhesion inhibitory factors produced by cytokine activated endothelial cells. These factors designated endothelial-derived IL-8 find use in the diagnosis and treatment of inflammation and in the protection of endothelial cells from neutrophil mediated damage.
Type:
Grant
Filed:
February 25, 1993
Date of Patent:
April 12, 1994
Assignee:
Brigham and Women's Hospital
Inventors:
Michael A. Gimbrone, Jr., M. Elyse Wheeler
Abstract: Methods of treating patients with new compositions intended for use in dietetics, reanimation and therapeutics are provided. The new compositions contain a protein fraction based on three types of minipeptides. The method involves the step of administering a therapeutically effective amount of a composition including specific minipeptides including casein minipeptides with and without phosphopeptides wherein the quantity of selected minipeptides is chosen to assure a proper balance between the sulfur containing amino acids and phosphors bound to proteins.
Abstract: A method for the prophylaxis or direct treatment of inflammatory diseases or injuries in a patient which comprises administering to the site of the disease or injury an effective amount of at least one serine protease inhibitor, its salts, derivatives or analogs which bind with the mast cell mediators, T-cell mediators or kallikrein.
Abstract: The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of modified C-reactive protein ("mCRP"). The invention also provides a method of treating cancer in a mammal comprising administering to the mammal mCRP in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, or cytokine. The mCRP may be administered to the mammal in a pharmaceutically-acceptable carrier or in liposomes. The invention further provides a method of identifying cancer cells in a mammal using mCRP as an imaging agent.
Type:
Grant
Filed:
April 24, 1992
Date of Patent:
February 1, 1994
Assignees:
Immtech International, Inc., Northwestern University
Inventors:
Lawrence A. Potempa, John J. Kresl, Byron E. Anderson
Abstract: An inhibitor of the proliferation of herpesviruses and of the recurrence of affections caused by their latent infection, which is an active material obtained by fractional purification of the aqueous extract from cultured Lentinus edodes mycelia.
Abstract: A nutritionally complete feeding composition contains soluble fiber, especially hydrolyzed guar gum or pectin. This composition provides nourishment to colon cells, preventing bacterial sepsis and also preventing diarrhea.
Abstract: A method is provided to enhance the permeability of the blood-nerve barrier or the blood-brain barrier to neuroactive proteins, comprising glycating said proteins prior to bringing them into contact with said barriers.
Type:
Grant
Filed:
November 6, 1991
Date of Patent:
November 9, 1993
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. When the bacteriocin compositions are combined with a suitable carrier with each component present in sufficient quantities such that the composition is effective against Gram negative bacteria in addition to Gram positive bacteria, they become enhanced, rapid acting, broad range bactericides suitable for a variety of applications.
Type:
Grant
Filed:
April 17, 1992
Date of Patent:
November 9, 1993
Assignee:
Applied Microbiology, Inc.
Inventors:
Peter Blackburn, June Polak, Sara-Ann Gusik, Stephen D. Rubino
Abstract: A composition comprising a magainin peptide or an analogue or derivative thereof, and at least one member selected from the group consisting of a PGLa peptide or analogue or derivative thereof, and an XPF peptide or analogue or derivative thereof. The composition is employed as a pharmaceutical.
Abstract: Disclosed is an immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine or a salt thereof in combination, which shows a strong therapeutic effect by synergistic action and weak side effects. The immunostimulant agent may further contain another chemotherapeutic agent and/or another immunotherapeutic agent.
Abstract: Non-surgically correctable infertility or sub-fertility in adult men having poor semen quality is treated with injections of human Growth Hormone (hGH) in daily doses of 1-10 IU/m.sup.2 or in doses in combination with gonadotrophins. Increase in total semen volume and total sperm number per ejaculate up to normal figures is obtained.
Abstract: The invention relates in general to the prevention and treatment of microbial infections in transplant patients. More particularly, the invention concerns the use of lymphokines, and specifically gamma interferon (IFN-.gamma.) for the prophylaxis and treatment of microbial infections in transplant recipients, without increasing the incidence of graft rejections.
Type:
Grant
Filed:
October 7, 1991
Date of Patent:
September 28, 1993
Assignee:
Genentech, Inc.
Inventors:
Christine Czarniecki, Jon B. Klein, A. David Slater, Gerald Sonnenfeld
Abstract: The invention concerns the use of IgE-binding factor (IgE-bf) for the stimulation of the maturation, i.e. of the differentiation and proliferation, of myeloid precursor cells in context with interleukin-1 (IL-1). The invention further concerns a a pharmaceutical preparation comprising IgE-bf either alone or in combination with IL-1 for the treatment or prevention of diseases by stimulating the maturation of myeloid precursor cells.
Abstract: Phosphorylated insulins which can be prepared from chemically extracted pharmacological insulins by gentle treatment with phosphorus oxychloride, have been shown to have reduced bioactivity by mouse convulsion assay, but such phosphorylated insulins reduce hyperglycemia when administered to diabetic subjects without inducing hypoglycemia.
Abstract: This invention provides a feline vaccine composition comprising an immunogenically active component having inactivated mammalian chlamydial cells or antigens derived therefrom, in combination with an effective amount of an immunogenically suitable adjuvant; and a veterinary pharmaceutically acceptable carrier or diluent. The vaccine composition is useful to prevent chlamydia, e.g. C. psittaci, infections or diseases in felines, and may also be combined with other vaccine compositions or therapy. A process for producing C. psittaci suitable for use in the production of safe and effective chlamydia vaccines, and a method for preventing chlamydia infections or diseases in felines, are also provided.
Type:
Grant
Filed:
November 7, 1990
Date of Patent:
September 7, 1993
Assignee:
American Home Products Corporation
Inventors:
Hsien-Jue Chu, Lloyd Chavez, William M. Acree, Lucille W. S. Chang
Abstract: A method for degrading fibrin deposits and preventing such deposits associated with pathological conditions is described, which comprises administering to a subject in need of such treatment a therapeutically effective amount of IL-4 activity, optionally in association with one or more pharmaceutically acceptable carriers or excipients. There is also described thrombolytic compositions which comprise IL-4 or a derivative thereof possessing IL-4 activity together with a pharmaceutically acceptable carrier or excipient.
Abstract: The present invention relates to a method of treatment of functional bowel disease in mammals. More specifically, this invention contemplates prophylaxis and treatment of functional bowel disease in mammals by the administration of antagonists of corticotropin releasing factor. The present invention also relates to pharmaceutical compositions of these antagonists useful in the treatment of functional bowel disease in mammals.
Abstract: A method for treating a cancer includes administration of an endotoxin to a patient at least a portion of whose neoplastic cells express the CD14 surface receptor. The endotoxin can be administered concurrently or sequentially with a binding protein capable of binding the endotoxin and, for example, where the endotoxin is a lipopolysaccharide or a nontoxic portion of a lipopolysaccharide, it may for example be administered concurrently with a lipopolysaccharide binding protein. Also, the method including a step of first determining whether a portion of the patient's neoplastic cells express the CD14 surface receptor and, if not, administering to the patient prior to or concurrently with the endotoxin a cytokine. Also, a composition for treating a cancer, that includes an endotoxin in combination with at least one cytokine. Administration of the composition can provide more effective treatment of cancers than administration of a composition containing one or more cytokines alone.
Abstract: A method for the prophylaxis or direct treatment of mast cell implicated pulmonary diseases which comprises administering an effective amount of a corticosteroid and at least one serine protease inhibitor, its salts, derivatives or analogs which bind with the mediators of mast cells or T-cells.